Rgd-enriched gelatine-like proteins with enhanced cell binding

ABSTRACT

The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchordependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems.

FIELD OF THE INVENTION

The invention relates to RGD-enriched gelatines that are used forattachment to integrins. The invention further relates to cell supportscoated with RGD-enriched gelatines. Said cell supports may be of use incell culture work and applications involving cell cultures of anchordependent cells and also in a large variety of medical applications.

BACKGROUND OF THE INVENTION

Cell culture of animal cells, in particular mammalian cells, isimportant for the production of many important (genetically engineered)biological materials such as vaccines, enzymes, hormones and antibodies.The majority of animal cells are anchorage-dependent and requireattachment to a surface for their survival and growth.

Routinely, anchorage-dependent cells have been cultivated on the wallsof for instance tissue culture flasks and roller bottles. As thenecessity has developed to provide large amounts of certain antiviralvaccines, genetically engineered proteins, and other cell-derivedproducts, improvements have been made to develop new systems for largerscale production of cells.

One such an improvement started with the development of microcarriers in1967 by Van Wezel (Van Wezel, A. L. Nature 216:64-65 (1967)). Van Wezelmade micro-carriers composed of cross-linked dextran beads charged withtertiary amine groups (DEAE). He demonstrated the attachment and growthof cells on these positively charged DEAE-dextran beads suspended inculture media in a stirred vessel. Thus, in microcarrier cell culturescells grow as monolayers on small spheres which are in suspension. Byusing microcarriers it is possible to achieve yields of several millioncells per millilitre. Over the years various types of microcarriers havebeen developed. For instance glass beads and polystyrene beads have beendescribed. Cross-linked dextran, like the first microcarriers, is stillthe most popular bead material.

Some advantages of microcarrier cultures over other methods oflarge-scale cultivation are: i) high surface area to volume ratio can beachieved which can be varied by changing the microcarrier concentrationleading to high cell densities per unit volume with a potential forobtaining highly concentrated cell products; ii) cell propagation can becarried out in a single high productivity vessel instead of using manylow productivity units, thus achieving a better utilisation and aconsiderable saving of medium; iii) since the microcarrier culture iswell mixed, it is easy to monitor and control different environmentalconditions such as pH, pO₂, pCO₂ etc.; iv) cell sampling is easy; v)since the beads settle down easily, cell harvesting and downstreamprocessing of products is easy; vi) microcarrier cultures can berelatively easily scaled up using conventional equipment like fermentersthat have been suitably modified.

When developing further improvements the following requirements for anoptimum microcarrier should be met: i) the surface properties of thebeads should be such that cells can adhere and proliferate rapidly,preferably the contour should be even; ii) the density of the beadsshould be slightly more than that of the culture medium, so as tofacilitate easy separation; conventional culture media are aqueous innature and have densities ranging from 1.03-1.09 g/cc, however, thedensity should not exceed a certain limit the optimum range being1.03-1.045 g/ml; gentle stirring, which will not harm theshear-sensitive cells, should be sufficient to keep them in suspension,if the beads settle cell growth will be prevented; iii) thesize-distribution of the beads should be narrow so that an evensuspension of all microcarriers is achieved and cells attain confluencyat approximately the same time; also, clustering of microcarriers insolution should be prevented; iv) the optical properties should enableeasy microscopic observation; v) they should be non-toxic not only forthe survival and good growth of the cells but also for cell cultureproducts that are used for veterinary or clinical purposes; vi) thematrix of the beads should be such that collisions, which occur duringstirring of the culture, do not cause fragmentation of the beads.

An important modification in the development of improved microcarriersis the coating of core particles with collagen. The advantage of usingcollagen is that it is a promoter for both cell attachment and cellgrowth. In addition cells can be easily detached by proteolytic enzymes.Also microcarriers coated with fibronectin, which is a cell adhesionpromoter, have been described.

Cell surface receptors that are involved in binding are identified asintegrins. More than 20 integrins are known, each having differentligand specificities. Many integrins can recognise the amino acidsequence RGD (arginine-glycine-aspartic acid). The number of proteinsknown to comprise an RGD sequence is limited, estimated to beapproximately 400. Also not every occurring RGD sequence is involved ina binding function. In particular RGDS is known to be involved in celladhesion. It is known that natural native collagens comprise the aminoacid sequence RGD. Examples are for instance murine COL1A1-1, COL1A1-2,COL1A1-3, rat COL3A1, human COL1A-1, COL2A-1, COL3A-1 and COL1A1-2. Cellattachment to collagen follows a highly specific mechanism, as cellssecrete the protein fibronectin which has a specific affinity forcollagen. After attachment to collagen, the fibronectin bindssubsequently to the integrin proteins in the cell.

Gelatine is a degradation product of collagen, and the term trulyreflects a heterogeneous mixture of proteins and peptides with MW'sranging from 5,000 up to more than 400,000 daltons. A certain fractionof these gelatine polymers will contain an RGD motive and a certainfraction of hydrolysed molecules will not have such an RGD motif.

Burgess and Myles describe the chemical coupling of RGD containingpeptides to type I collagen, which method is complicated and introducesimpurities into the target materials and has limited modificationfreedom (Ann Biomed Eng 2000 Jan;28(l):1 10-118).

U.S. Pat. No. 5,512,474 aims at a good cell adhesion by combining celladhesion factors and positively charged molecules to the surface of acell culture support. Fibronectin is identified as a cell adhesionintermediate.

U.S. Pat. No. 5,514,581 is concerned with the production ofsubstantially new polypeptides by using automated methods for thechemical synthesis of DNA in combination with recombinant DNAtechnology. The patent describes non-natural polypeptides which may beof use in commercial applications for which known, naturally occurringpolypeptides are not appropriate. Although the artificial proteins couldcontain an RGD sequence, the resulting bio-polymers have littleresemblance with naturally occurring proteins, and will causeimmunological problems in case of medical applications.

Cell attachment also plays an important role in medical applicationssuch as wound treatment (including artificial skin materials), bone andcartilage (re)growth and implantations and artificial blood vesselmaterials. Thus in medical applications often the demand is that amaterial has a biocompatible coating in terms of cell attachment. Ingeneral collagen is preferred over structures like those described inU.S. Pat. No. 5,514,581 since collagen has a low antigenicity and ispresent in both skin and bone or cartilage. Microcarriers coated withgelatine are applied, but also porous matrixes of collagen are used. Anexample is collagen coated beads to grow keratinocytes and thesubsequent transplantation of the beads containing keratinocytes topromote healing of wounds is described in U.S. Pat. No. 5,972,332.Another area of interest in relation to cell attachment is the blockingof attachment receptors of cells. For instance by blocking theattachment receptors cancer metastasis may be influenced or inhibited.Also smaller peptides with RGD sequences are used to block the bindingsites on cells thus preventing unwanted interactions like aggregation orcoagulation as described for example in EP 0,628,571.

There is however an urgently felt need for further improvements ofmaterials for use in applications involving cell attachment. Thefibronectin-mediated cell attachment mechanism is effectuated to attachcells to natural gelatines. However, natural gelatines are not safe interms of prion and virus impurities. The RGD mediated mechanism for cellattachment is effectuated by several artificial bio-polymers, producedby chemical or by recombinant DNA technologies. However, these materialshave non-natural sequences and have a risk of initiating animmunological response which could result in serious medical problems.

Whereas often the terms ‘collagen’, ‘collagen-related2 ,collagen-derived’ or the like are also used in the art, the term‘gelatine’ or ‘gelatine-like’ protein will be used throughout the restof this description. Natural gelatine is a mixture of individualpolymers with MW's ranging from 5,000 up to more than 400,000 daltons.The terms cell adhesion and cell attachment are used interchangeably.Also the terms RGD sequence and RGD motif are used interchangeably.

SUMMARY OF THE INVENTION

It is an object of the invention to provide polypeptides or peptideswhich have an improved, preferably a high cell binding capacity andselectivity. A further object of the invention is to provide cellbinding peptides or polypeptides with no risk for viral infection orother pathogens or health related hazards such as prions. It is also anobject of the invention to provide peptides or polypeptides which do notevoke any immune response when being in contact, directly or indirectly,with the human immune system.

Surprisingly it was found that all these objectives were met by anRGD-enriched gelatine with a more even distribution of RGD sequencesthan occurring in a natural gelatine and with a minimum level of RGDsequences. The level of RGD sequences is expressed as a percentage. Thispercentage is calculated by dividing the number of RGD motifs divided bythe total number of amino acids and multiplying the result with 100.Note that the highest percentage of RGD motifs, i.e. in a gelatineconsisting solely of RGD motifs, would be 33.33. Also, the number of RGDmotifs is an integer starting from 1, 2, 3, . . . etc.

The RGD-enriched gelatine of the invention is highly suitable forcoating a cell culture support for growing anchor-dependant cell types.Thus the invention relates to a cell support comprising an RGD-enrichedgelatine in which the percentage of RGD motifs related to the totalnumber of amino acids is at least 0.4 and if the RGD-enriched gelatinecomprises 350 amino acids or more, each stretch of 350 amino acidscontains at least one RGD motif.

The invention provides RGD-enriched gelatine for binding to integrins inwhich the percentage of RGD motifs related to the total number of aminoacids is at least 0.4 and if the RGD-enriched gelatine comprises 350amino acids or more, each stretch of 350 amino acids contains at leastone RGD motif and said gelatine consists for at least 80% of one or moreparts of native human collagen sequences and said parts of native humancollagen sequences have a length of at least 30 amino acids.

Also the invention relates to the use of an RGD-enriched gelatineaccording to the invention as a coating on scaffolds for tissueengineering or on implant or transplant materials.

Further the RGD-enriched gelatine of the invention is designed for usein medical applications, in particular as a coating on implant ortransplant material or as a component of drug delivery systems, forinhibition of cancer metastasis, for prevention of platelet aggregation,for use as an antithrombic agent, for use as tissue adhesive, for dentalproducts, for use as artificial skin matrix material and for use aftersurgery to prevent tissue adhesion Use of an

DESCRIPTION OF THE INVENTION

The present invention is directed to peptides polypeptides or proteins,in particular to gelatines or gelatine-like proteins, which are highlysuitable for cell adhesion and can be used in medical orbiotechnological applications. More specifically the invention isdirected to cell binding peptides or polypeptides that have a lowantigenicity and that can be used without the risk of transferringpathological factors such as viruses, prions and the like.

It was found, surprisingly, that it is possible to obtain peptides orpolypeptides with excellent cell attachment properties and which do notdisplay any health related risks by production of RGD-enriched gelatinesin which the percentage of RGD motifs related to the total number ofamino acids is at least 0.4. If the RGD-enriched gelatine comprises 350amino acids or more, each stretch of 350 amino acids contains at leastone RGD motif. Preferably the percentage of RGD motifs is at least 0.6,more preferably at least 0.8, more preferably at least 1.0, morepreferably at least 1.2 and most preferably at least 1.5. Such(recombinant) gelatines are very suitable for coating cell culturesupports which can be used in biotechnological processes or in medicalapplications. In the context of this invention a “cell support” is asubstance that gives support to cells to facilitate their growth andmultiplication.

A percentage RGD motifs of 0.4 corresponds with at least 1 RGD sequenceper 250 amino acids. The number of RGD motifs is an integer, thus tomeet the feature of 0.4%, a gelatine consisting of 251 amino acidsshould comprise at least 2 RGD sequences. Preferably the RGD-enrichedrecombinant gelatine of the invention comprises at least 2 RGD sequenceper 250 amino acids, more preferably at least 3 RGD sequences per 250amino acids, most preferably at least 4 RGD sequences per 250 aminoacids. In a further embodiment an RGD-enriched gelatine according to theinvention comprises at least 4 RGD motifs, preferably 6, more preferably8, even more preferably 12 up to and including 16 RGD motifs.

The term ‘RGD-enriched gelatine’ in the context of this invention meansthat the gelatines of this invention have a certain level of RGD motifs,calculated as a percentage of the total number of amino acids permolecule and a more even distribution of RGD sequences in the amino acidchain than a natural gelatine. In humans up to date 26 distinct collagentypes have been found on the basis of protein and or DNA sequenceinformation (see K. Gelse et al, Collagens-structure, function andbiosynthesis, Advanced Drug Delivery reviews 55 (2003) 1531-1546).Sequences of natural gelatines, both of human and non-human origin, aredescribed in the Swiss-Prot protein database. Herebelow follows a listof suitable human native sequences, identified by their entry name andprimary accession number in the Swiss-Prot database, that may serve as asource of parts of natural sequences comprised in the RGD-enrichedgelatines of this invention.

CA11 HUMAN (P02452) Collagen alpha 1(I) chain precursor. {GENE:COL1A1}—Homo sapiens (Human)

CA12 HUMAN (P02458) Collagen alpha 1(II) chain precursor [Contains:Chondrocalcin]. {GENE: COL2A1}—Homo sapiens (Human)

CA13 HUMAN (P02461) Collagen alpha 1 (111) chain precursor. {GENE:COL3A1}—Homo sapiens (Human)

CA14 HUMAN (P02462) Collagen alpha 1(IV) chain precursor. {GENE:COL4A1}—Homo sapiens (Human)

CA15 HUMAN (P20908) Collagen alpha 1(V) chain precursor. {GENE:COL5A1}—Homo sapiens (Human)

CA16 HUMAN (P12109) Collagen alpha 1(VI) chain precursor. {GENE:COL6A1}—Homo sapiens (Human)

CA17 HUMAN (Q02388) Collagen alpha 1(VII) chain precursor (Long-chaincollagen) (LC collagen). {GENE: COL7A1}—Homo sapiens (Human)

CA18 HUMAN (P27658) Collagen alpha 1(VIII) chain precursor (Endothelialcollagen). {GENE: COL8A1}—Homo sapiens (Human)

CA19 HUMAN (P20849) Collagen alpha 1(IX) chain precursor. {GENE:COL9A1}—Homo sapiens (Human)

CA1A HUMAN (Q03692) Collagen alpha 1(X) chain precursor. {GENE:COL10A1}—Homo sapiens (Human)

CA1B HUMAN (P12107) Collagen alpha 1(XI) chain precursor. {GENE:COL11A1}—Homo sapiens (Human)

CA1C HUMAN (Q99715) Collagen alpha 1(XII) chain precursor. {GENE:COL12A1}—Homo sapiens (Human)

CA1E HUMAN (P39059) Collagen alpha 1(XV) chain precursor. {GENE:COL15A1}—Homo sapiens (Human)

CA1F HUMAN (Q07092) Collagen alpha 1(XVI) chain precursor. {GENE:COL16A1}—Homo sapiens (Human)

CA1G HUMAN (Q9UMD9) Collagen alpha 1(XVII) chain (Bullous pemphigoidantigen 2) (180 kDa bullous pemphigoid antigen 2). {GENE: COL17A1 ORBPAG2 OR BP180}—Homo sapiens (Human)

CA1H HUMAN (P39060) Collagen alpha 1(XVIII) chain precursor [Contains:Endostatin]. {GENE: COL18A1}—Homo sapiens (Human)

CA1I HUMAN (Q14993) Collagen alpha 1(XIX) chain precursor (Collagenalpha 1(Y) chain). {GENE: COL19A1}—Homo sapiens (Human)

CA21 HUMAN (P08123) Collagen alpha 2(I) chain precursor. {GENE:COL1A2}—Homo sapiens (Human)

CA24 HUMAN (P08572) Collagen alpha 2(IV) chain precursor. {GENE:COL4A2}—Homo sapiens (Human)

CA25 HUMAN (P05997) Collagen alpha 2(V) chain precursor. {GENE:COL5A2}—Homo sapiens (Human)

CA26 HUMAN (P12110) Collagen alpha 2(VI) chain precursor. {GENE:COL6A2}—Homo sapiens (Human)

CA28 HUMAN (P25067) Collagen alpha 2(VIII) chain precursor (Endothelialcollagen). {GENE: COL8A2}—Homo sapiens (Human)

CA29 HUMAN (Q14055) Collagen alpha 2(IX) chain precursor. {GENE:COL9A2}—Homo sapiens (Human)

CA2B HUMAN (P13942) Collagen alpha 2(XI) chain precursor. {GENE:COL11A2}—Homo sapiens (Human)

CA34 HUMAN (Q01955) Collagen alpha 3(IV) chain precursor (Goodpastureantigen). {GENE: COL4A3}—Homo sapiens (Human)

CA35 HUMAN (P25940) Collagen alpha 3(V) chain precursor. {GENE:COL5A3}—Homo sapiens (Human)

CA36 HUMAN (P12111) Collagen alpha 3(VI) chain precursor. {GENE:COL6A3}—Homo sapiens (Human)

CA39 HUMAN (Q14050) Collagen alpha 3(IX) chain precursor. {GENE:COL9A3}—Homo sapiens (Human)

CA44 HUMAN (P53420) Collagen alpha 4(IV) chain precursor. {GENE:COL4A4}—Homo sapiens (Human)

CA54 HUMAN (P29400) Collagen alpha 5(IV) chain precursor. {GENE:COL4A5}—Homo sapiens (Human)

CA64 HUMAN (Q14031) Collagen alpha 6(IV) chain precursor. {GENE:COL4A6}—Homo sapiens (Human)

EMD2 HUMAN (Q96A83) Collagen alpha 1 (XXVI) chain precursor (EMI domaincontaining protein 2) (Emu2 protein) (Emilin and multimerin-domaincontaining protein 2). {GENE: EMID2 OR COL26A1 OR EMU2}—Homo sapiens(Human)

Natural gelatines are known to comprise RGD sequences. It is importanthowever that a gelatine molecule does not contain too large partswithout RGD motifs. Too large parts of gelatines without RGD sequencereduce the possibility of cell attachment when such a gelatine is usedfor instance as a coating on a microcarrier. Apparently not all RGDsequences in a gelatine are under all circumstances available for cellattachment. It was found that cell attachment was remarkably improved ingelatines according to the invention compared to gelatines having astretch of amino acids of more than 350 without an RGD sequence. Forgelatines of less than 350 amino acids it is sufficient to have apercentage of RGD sequences of at least 0.4. Note that for a gelatine of251-350 amino acids this means that at least 2 RGD motifs are present.

In a preferred embodiment the RGD-enriched gelatine is prepared byrecombinant DNA technology. Recombinant gelatines of this invention arepreferably derived from collageneous sequences. Nucleic acid sequencesencoding collagens have been generally described in the art. (See, e.g., Fuller and Boedtker (1981) Biochemistry 20: 996-1006; Sandell et al.(1984) J Biol Chem 259: 7826-34; Kohno et al. (1984) J Biol Chem 259:13668-13673; French et al. (1985) Gene 39: 311-312; Metsaranta et al.(1991) J Biol Chem 266: 16862-16869; Metsaranta et al. (1991) BiochimBiophys Acta 1089: 241-243; Wood et al. (1987) Gene 61: 225-230;Glumoffet al. (1994) Biochem Biophys Acta 1217: 4148 ; Shirai et al.(1998) Matrix Biology 17: 85-88; Tromp et al. (1988) Biochem J 253:919-912; Kuivaniemi et al. (1988) Biochem J 252: 633640; and Ala-Kokkoet al. (1989) Biochem J 260: 509-516.).

For pharmaceutical and medical uses, recombinant gelatines with aminoacid sequences closely related to or identical to amino acid sequencesof natural human collagens are preferred. More preferably the amino acidsequence of the inventive gelatine is designed by a repetitive use of aselected amino acid sequence of a human collagen. A part of a naturalcollagen sequence comprising an RGD motif is selected. The percentage ofRGD motifs in such a selected sequence depends on the chosen length ofthe selected sequence, selection of a shorter sequence results in ahigher RGD percentage. Repetitive use of a selected amino acid sequenceresults in a gelatine with a higher molecular weight, which isnon-antigenic and with an increased number of RGD motifs (compared tonatural gelatines or collagens). Natural non-human sources includenon-human mammalian sources, such as bovine, porcine, and equinesources, and other animal sources, such as chicken, murine, rat andpiscine sources.

Thus in a preferred embodiment the RGD-enriched gelatine according tothe invention comprises a part of a native human collagen sequence.Preferably the RGD-enriched gelatine consists for at least 80 % of oneor more parts of one or more native human collagen sequences. Each ofsuch parts of human collagen sequences should have a length of at least30 amino acids, more preferably at least 45 amino acids, most preferablyat least 60 amino acids, up to e.g. 240, preferably up to 150, mostpreferably up to 120 amino acids, each part preferably containing one ormore RGD sequences. Preferably the RGD-enriched gelatine consists of oneor more parts of one or more native human collagen sequences.

An example of a suitable source of a gelatine according to thisinvention is human COL1A1-1. A part of 250 amino acids comprising an RGDsequence is given in SEQ ID NO: 1.

RGD sequences in gelatines can adhere to specific receptors on the cellwall called integrins. These integrins differ in their specificity inrecognising cell binding amino acid sequences. Although both naturalgelatine and, for example, fibronectin may contain RGD sequences,gelatine can bind cells that will not bind to fibronectin and viceversa. Therefore fibronectin comprising RGD sequences cannot alwaysreplace gelatine for cell adhesion purposes.

Recombinantly produced gelatine does not suffer from the disadvantage ofcontamination with pathogens originating from the animal from which thegelatine was derived.

When used as or in combination with a cell culture support, gelatinefunctions as a cell binding polypeptide. It has the advantage over otherpolypeptides that it can also be metabolised by the cells growing on it.A further advantage is that it can be easily digested enzymatically sothat cells can be harvested with almost 100% yield. A further advantageof recombinantly produced gelatines is that the molecular weight (MW)can be kept uniform. Natural gelatines unavoidably have a broadmolecular weight distribution with peptides smaller than 5,000 kD up tolarge polymers with a molecular weight larger than 400,000 kD, resultingfrom the production method. In particular in combination withmicrocarrier core beads as cell culture support, a disadvantage ofsmaller peptides is that they will adhere inside finer pores of themicrocarrier which cannot be reached by the cells so that part of theadded gelatine is not used. With recombinant production methods thegelatine can be designed with the desired molecular weight, preventingthis undesired loss of material.

In a further embodiment the gelatine of the invention has a molecularweight of about 30 kDa to about 200 kDa to coat a core bead resulting ina cell culture support in the form of a microcarrier.

In addition to the presence of RGD sequences, the molecular weight rangeof the gelatine offers striking advantages and provides the resultingmicrocarriers with advantageous properties. A key problem in the processof coating microcarrier core beads is the clumping together of beads. Inparticular such clumping reduces the available surface area for cellattachment and disturbs the size distribution of the microcarriersrendering them unusable.

It was found that the relatively small fraction of high MW gelatinepolymer molecules within a natural gelatine batch is to a large extentresponsible for the clumping together of beads during the microcarrierproduction process. It was concluded that when such a gelatine polymerwith high molecular weight adheres to a core bead, a part of the peptidechain may point away from the surface of the core bead and as such be ananchor for other beads and thus induce coagulation.

It is therefore preferred according to the present invention to coatcore beads with gelatine having a molecular weight of less than 200 kDa,more preferably less than 150 kDa.

Furthermore, it was found that the small MW fraction of a naturalgelatine shows unfavourable microcarrier coating characteristics. Thissmall MW fraction showed a lower adsorption force to the microcarrierbeads, and, thus, when not being adsorbed it promotes microcarrierclumping after the chemical cross-linking step. Additionally, in case ofthe use of lower concentrations of the gelatine in the microcarriercoating process to prevent clumping, the small MW fraction is at firstinstance adsorbed to the microcarrier but has the unfavourablecharacteristic of entering the small pores of a microcarrier porous corebeads, thereby not contributing to the attachment of the cells on themicrocarrier during the cell culture step. Thus, the molecular weight ofthe gelatine should be high enough to perform the actual coating processeffectively resulting in efficient coating, to prevent clumping of thecore beads and to prevent loss of the gelatine. Thus the molecularweight of the gelatine should be higher than 30 kDa, preferably higherthan 60 kDa, most preferably higher than 70 kDa.

Preferably the molecular weight of the gelatine or gelatine-like proteinis uniform, with more than 75%, preferably more than 85%, morepreferably more than 95% or even at least 98% of the gelatine orgelatine-like protein having a uniform MW within 20% from the selectedmolecular weight.

By selecting a molecular weight, within the above specified range, in acoating process the viscosity of the gelatine or gelatine-like proteincoating solution can be accurately controlled. Complete or, moreimportant, partial gelling of such a gelatine solution can be preventedwhile being able to select a high as possible concentration of thegelatine.

The uniform gelatine ensures a process of identically coatedmicrocarriers. The uniform coating process allows the use of a minimumamount of gelatine and the use of a minimum volume of gelatine coatingsolution. All this results in a far more efficient coating process thanthat is known in the art.

In one embodiment of the invention non-porous core beads are coated withgelatine of the invention. Suitably non-porous core beads are made ofpolystyrene or glass. Other suitable non-porous materials are known tothose skilled in the art.

A particular advantageous embodiment is the process of the inventionwherein porous core beads, such as beads from modified dextran orcross-linked cellulose, or (porous) polystyrene, in particularDEAE-dextran, are coated with gelatine of the invention. Other suitableporous materials are known to those skilled in the art, and include e.g.other chemically modified or non-modified polysaccharides. The lowermolecular weight limit prevents that gelatine or gelatine-like proteinenters the pores of the porous core beads thereby preventing inefficientcoating of the beads and unnecessary loss of gelatine or gelatine-likeprotein.

The size of the beads may vary from 50 μm to 500 μm. Typical meanmicrocarrier bead sizes are about 100, about 150 or about 200 μm inphysiological saline. Size ranges with at least 90% of the beads lyingwithin the range may vary from 80-120 μm, 100-150 μm, 125-175 μm or150-200 μm.

A wide range of cells may be cultured on microcarriers. For instance,cells from invertebrates, from fish, birds and cells of mammalian originmay be cultivated on microcarriers. Transformed and normal cell lines,fibroblastic and epithelial cells and even genetically engineered cellsmay be cultivated on microcarriers for various biological applicationssuch as for the production of immunologicals like interferons,interleukins, growth factors etc. Cells cultured on microcarriers alsoserve as hosts for a variety of viruses that are used as vaccines likefoot and mouth disease or rabies.

Microcarrier cultures have a wide number of applications other than masscultivation as well. Cells growing on microcarriers serve as anexcellent tool for studying different aspects of cell biology such ascell-to-cell or cell-to-substratum interactions. Cell differentiationand maturation, metabolic studies may also be carried out usingmicrocarriers. Such cells can also be used for electron microscopicstudies or for the isolation of cell organelles such as the cellmembrane. Also, this system is essentially a three-dimensional systemand serves as a good 3-D model. Similarly, co-cultivation of cells canbe done using this system. Thus applications include the production oflarge quantities of cells, viruses and cell products (e.g. interferon,enzymes, nucleic acids, hormones), studies on cell adhesion,differentiation and cell function, perfusion column culture systems,microscopy studies, harvesting mitotic cells, isolation of cells,membrane studies, storage and transport of cells, assays involving celltransfer and studies on uptake of labelled compounds.

Microcarriers may also be used for the depletion of macrophages from apopulation of spleen cells. DEAE-dextran microcarriers can potentiatestimulation of lymphocytes by concanavalin A (con A). Microcarrier beadsconfluent with allogenic tumour cells can be injected in mice toincrease humoral and cell-mediated immunity. Plant protoplasts can beimmobilised on DEAE-dextran microcarriers.

As a result of the large surface area to volume ratio provided bymicrocarriers, they can successfully be used for a variety of biologicalproductions on a laboratory scale as well as an industrial scale of forinstance even 4000 litres or more.

Large scale production of expressed products can be accomplished withgelatine-coated microcarriers. Loading of microcarriers in productionscale bioreactors is generally 20 g/l, but may be increased up to 40g/l. Microcarriers may be used in batch and perfusion systems, instirred cultures, and wave bioreactors, as well as to increase thesurface area of traditional stationary monolayers and roller cultures.

In a further preferred embodiment the gelatine or gelatine-like proteinis in essence free of hydroxyproline residues. Hydroxylation is arequirement for the formation of triple helices in collagen and plays arole in gelation of gelatine. In particular less than 10%, morepreferably less than 5% of the amino acid residues of the recombinantgelatines are hydroxyprolines, preferably the recombinant gelatine isfree from hydroxyprolines in applications where the gelling capabilityof the recombinant gelatine is unfavourable. The hydroxyproline-freerecombinant gelatines can be used in higher concentrations, and thesolutions will be less viscous requiring less vigorous agitation,resulting in less shear forces on the cultured cells. As described in WO02/070000 A1, recombinant gelatines which are is essence free fromhydroxyprolines do not show immune reactions involving IgE in contrastto natural gelatine.

A process for the preparation of collagen coated microcarriers isdescribed in U.S. Pat. No. 4,994,388. In short providing a core beadwith a collagen coating is performed in two steps: coating and fixing.The core beads are suspended in an acidic, aqueous collagen solution(0.01-0.1N acetic acid), and the solution is evaporated to dryness. Thedry, collagen-coated beads are then suspended in a solution whichcontains a protein cross-linking agent such as glutaraldehyde, thuscross-linking the collagen coating. Alternatively, the core beads wettedwith the collagen solution are not dried entirely before the start ofthe fixing step. Variations in coating conditions and alternativecoating processes are well within the competence of those skilled in theart.

Recombinant structures can also be designed to incorporate additionalpositively charged groups, as in U.S. Pat. No. 5,512,474, by building inadditional arginines, lysines or histidines. Recombinant production ofgelatines allows easy manipulation of the number of positively chargedamino acids, meaning positively charged at the pH of the cell culture,in the produced protein. In particular arginine, lysine and histidinecarry positive charges. It is well within the reach of the skilledperson to design a gelatine with a net positive charge at the pH of theparticular cell culture of interest. Cells are normally cultured at a pHof 7-7.5. Thus in a further embodiment of the invention a gelatine orgelatine-like protein is used that has a net positive charge at pH7-7.5. Preferably the net positive charge is +2, +3, +4, +5, +10 orhigher. Thus in a further embodiment the invention relates to a gelatinethat has a net positive charge at pH 7-7.5. Preferably the net positivecharge is +2, +3, +4, +5, +10 or higher

In a further embodiment the invention relates to RGD-enriched gelatinesof at most 10 kDa, preferably at most 5 kDa. Such an RGD-enrichedgelatine containing at least one RGD sequence can be used to blocksurface receptors on cells. Blocking of receptors of cells is applied infor example inhibiting angiogenesis or in blocking integrins on cardiacfibroblasts.

Cell supports coated with recombinant gelatine according to theinvention, on which cells have been grown can be applied during, forexample, transplantation of skin or wound treatment or to enhance boneor cartilage (re)growth. It is also possible to coat implant materialswith recombinant gelatine of the invention to adhere cells which promoteimplantation.

Thus a specific embodiment is a cell support according to thisinvention, said cell support being a microcarier

Other particular embodiments are cell supports selected from the groupconsisting of an RGD-enriched coated implant or transplant material, anRGD-enriched coated scaffold for tissue engineering, (part of) a dentalproduct, (part of) a wound healing product, (part of) artificial skinmatrix material and (part of) a tissue adhesive.

A natural gelatine molecule in its primary amino acid sequence basicallyconsists of repeats of GXY triplets, thus approximately one third of thetotal number of amino acids is a glycine. The molecular weight ofgelatine is typically large, values of the molecular weight vary from10,000 to 300,000 Dalton and higher.

In a further embodiment the invention relates to RGD-enriched gelatineswhich are not glycosylated. Glycosylation takes place at the amino acidsAsn (N-glycosydic structures), or Ser or Thr (O-glycosydic structures).Glycosylation should be preferably prevented for applications where noimmune response is desired. The absence of Asn, Ser and Thr amino acidsin the primary sequence is an effective way to prevent the glycosylationin biotechnological production systems using for instance yeast cellcultures.

Furthermore, characteristic for gelatine is the unusual high content ofproline residues. Even more characteristic is that in natural gelatine anumber of the proline residues is hydroxylated. Most prominent site ofhydroxylation is the 4-position resulting in the presence in thegelatine molecule of the unusual amino acid 4-hydroxyproline. In atriplet 4-hydroxyproline is always found in the Y position. The presenceof the hydroxyproline residues is responsible for the fact that agelatine molecule in its secondary structure can adopt a helicalconformation. Thus, it is preferred that the gelatines to be usedaccording to the invention in applications in which the gelling propertyis unfavourable contain less than 5%, preferably less than 3%, mostpreferably less than 1% of hydroxyproline residues.

In this invention gelatine-like proteins are to be understood asproteins in which GXY triplets or stretches of GXY triplets areseparated by one or more amino acids.

The RGD-enriched gelatines according to the invention can be produced byrecombinant methods as disclosed in EP-A-0926543, EP-A-1014176 orWOO1/34646. Also for enablement of the production and purification ofgelatines of the invention reference is made to the examples inEP-A-0926543 and EP-A-1014176.

The preferred method for producing an RGD-enriched gelatine is bystarting with a natural nucleic acid sequence encoding a part of thecollagen protein that includes an RGD amino acid sequence. By repeatingthis sequence an RGD-enriched gelatine is obtained.

If X-RGD-Y is a part of the natural collagen amino acid sequence, a(part of a) gelatine with three RGD amino acid sequences would have thestructure -X-RGD-Y-(GXYG)_(n)-X-RGD-Y-(GXYG)n-X-RGD-Y-, with n being aninteger starting from 0. By varying n the number of RGD sequences on thetotal amino acids number can be controlled. A clear advantage of thismethod is that the amino acid sequence remains most natural and thus hasthe lowest risk of inducing immunological response in clinicalapplications.

Starting from a natural nucleic acid sequence encoding (part of) acollagen, also point mutations can be applied so as to yield a sequenceencoding an RGD sequence. Based on the known codons a point mutation canbe performed so that an RGX sequence after mutation will yield an RGDsequence, alternatively also an YGD sequence can be mutated to yield anRGD sequence. Also it is possible to carry out two mutations so that anYGX sequence will give an RGD sequence. Also it may be possible toinsert one or more nucleotides or delete one or more nucleotides givingrise to a desired RGD sequence.

Thus the gelatine-like proteins can be produced by expression of nucleicacid sequence encoding such polypeptide by a suitable micro-organism.The process can suitably be carried out with a fungal cell or a yeastcell. Suitably the host cell is a high expression host cells likeHansenula, Trichoderma, Aspergillus, Penicillium, Saccharomyces,Kluyveromyces, Neurospora or Pichia. Fungal and yeast cells arepreferred to bacteria as they are less susceptible to improperexpression of repetitive sequences. Most preferably the host will nothave a high level of proteases that attack the collagen structureexpressed. In this respect Pichia or Hansenula offers an example of avery suitable expression system. Use of Pichia pastoris as an expressionsystem is disclosed in EP-A-0926543 and EP-A-1014176. In one embodimentthe micro-organism is free of active post-translational processingmechanism such as in particular hydroxylation of proline and alsohydroxylation of lysine. In another embodiment the host system has anendogenic proline hydroxylation activity by which the recombinantgelatine is hydroxylated in a highly effective way. The selection of asuitable host cell from known industrial enzyme producing fungal hostcells specifically yeast cells on the basis of the required parametersdescribed herein rendering the host cell suitable for expression ofrecombinant gelatine-like proteins suitable in compositions according tothe invention in combination with knowledge regarding the host cells andthe sequence to be expressed will be possible by a person skilled in theart.

EXAMPLES Example 1

An RGD-enriched gelatine was produced by starting with the nucleic acidsequence that encodes for a part of the gelatine amino acid sequence ofhuman COL1A1-1. The methods as disclosed in EP-A-0926543, EP-A-1014176and WO 01/34646 were used. The sequence of this RGD-enriched gelatineaccording to the invention is given in SEQ ID NO: 2. A total of four RGDsequences are present in the molecule which corresponds to a level offour RGD sequences per 250 amino acids. In a similar way gelatines withone and two RGD sequences per 250 amino acids were made.

Example 2

Preparation of Microcarriers Beads

Polystyrene beads with an average diameter of 100 micrometers are used.The heterobifunctional cross-linking agent, BBA-EAC-NOS, is used tocovalently immobilise gelatine onto polystyrene beads. The BBA-EAC-NOSis added to the polystyrene beads and allowed to adsorb. Next, gelatineis added and is allowed to react with the NOS synthetic polymer toproduce covalent coupling to the spacer. Then the beads arephotoactivated (at 320 nm) to covalently immobilise the spacer (andcovalently coupled gelatine) to the polystyrene beads. Finally, looselyadherent gelatine is removed by overnight washing with the milddetergent Tween 20 in phosphate buffered saline (pH 7.2).

Cell Types and Culture Conditions

Green monkey kidney (Vero) cells, Chinese hamster ovary (CHO) cells,normal rat kidney fibroblast (NRK-49F) cells, and Madin Darby caninekidney (MDCK) cells were purchased from ATCC. All four cell types werepassaged and maintained in 75 cm@2 flasks at 37 DEG C. in a 5 % CO2environment. Vero and NRK-49F cells were cultured in Dulbecco's ModifiedEagles's Medium (DMEM), CHO cells were cultured in Ham's F-12 NutrientMixture, and MDCK cells were cultured in Minimum Essential Medium (MEM)with Earle's salts.

With the Vero and CHO cells, the medium was supplemented with 10% fetalbovine serum (FBS), 2 mM L-glutamine, 20 mM HEPES buffer, 1 mM sodiumpyruvate, 100 ug/ml streptomycin, and 100 units/ml penicillin (final pH7.1). With the NRK49F cells, the DMEM was supplemented with 5% FBS, 2 mML-glutamine, 1 mM sodium pyruvate, non-essential amino acids (0.1 mMeach), 100 ug/ml streptomycin, 100 units/ml penicillin, and 0.25 ug/mlof amphotericin B (final pH 7.1). With the MDCK cells, the MEM wassupplemented with 10% FBS, 2 mM L-glutamine, non-essential amino acids(0.1 mM each), and 100 ug/ml streptomycin, 100 units/ml penicillin, and0.25 ug/ml of amphotericin B (final pH 7.1).

In order to standardise the physiology of cells prior to eachexperiment, cells were passed into 150 cm@2 flasks 2 to 3 days prior toinoculation of microcarrier beads. Cells were trypsinised (0. 05 %trypsin, 0.53 mM EDTA in PBS) for removal from the flasks. For themicrocarrier experiments, the cells were centrifuged to remove thetrypsin medium and resuspended to about 1.times. 10@6 cells/ml inculture medium. The viable cell concentration was determined by Trypandye exclusion (0.4 % Trypan blue in 0.9% saline).

Cell Culture and Assays in Spinner Flasks

For the cell attachment assay, 20 mg/ml of coated polystyrene beads wereused and the cell concentration was 1.5.times. 10@5 cells/ml for eachcell type.

Microcarriers were cultured with 100 ml cultures being maintained in 250ml spinner vessels and stirred with suspended magnetic impellers (50rpm).

The kinetics of cell attachment were assayed as a decrease insupernatant cell concentration. For sample removal the agitation wasstopped briefly (about 30 seconds) at which time the microcarrierssettled and a supernatant sample was removed for cell quantitation asdescribed below.

For the cell counts, the cells were stained by mixing with an equalvolume of crystal violet (0.1% w/w) in 0.1 M citric acid, and thencounted with a hemocytometer. Cell depletion from the medium was used asan indicator of cells attached to beads

To verify that cells removed from the medium were indeed attached tomicrocarriers (and not lysed), cells attached to microcarriers werequantitated at the end of each cell attachment assay. One ml aliquots ofwell-agitated carrier medium were removed, the microcarriers wereallowed to settle, and the settled microcarriers were resuspended incrystal violet/citric acid as described above. After incubating 1 hourat 37 DEG C., the suspension was sheared by sucking into and out of aPasteur pipet to release nuclei, which were quantitated with ahemocytometer.

Gelatines with different RGD content were used as a microcarrier coatingaccording to the foregoing procedure. Recombinant gelatines with no,one, two and four RGD sequences per 250 amino acids were tested. A clearcorrelation was found between the number of RGD sites and the cellattachment. Best results were obtained at a level of four RGD sites per250 amino acids.

Example 3

An RGD-enriched gelatine was produced by starting with the nucleic acidsequence that encodes for a part of the gelatine sequence of humanCOL5A2. The methods as disclosed in EP-A-0926543, EP-A-1014176 and WOO1/34646 were used. The sequence of this RGD-enriched gelatine accordingto the invention is given in SEQ ID NO: 3. The percentage of RGD motifsin this sequence is 0.8 and a stretch of 435 amino acids without an RGDsequence is present.

The above mentioned gelatine was used as a microcarrier coatingaccording to the procedure in example 2. The cell attachment of thisgelatine was compared with a gelatine with two RGD motifs per 250 aminoacids as mentioned in example 1. Although the percentage of RGD motifsin both gelatines is the same (0.8%) the gelatine from example 1 clearlygave a much better cell attachment. This is attributed to the more evendistribution of RGD motifs.

1. A cell support comprising an RGD-enriched gelatine in which thepercentage of RGD motifs related to the total number of amino acids isat least 0.4 and if the RGD-enriched gelatine comprises 350 amino acidsor more, each stretch of 350 amino acids contains at least one RGDmotif.
 2. A cell support according to claim 1 in which in theRGD-enriched gelatine the percentage is at least 0.6, preferably atleast 0.8, more preferably at least 1.0, more preferably at least 1.2and most preferably at least 1.5.
 3. A cell support according to claim 1in which in the RGD-enriched gelatine the number of RGD motifs is atleast 4 per 250 amino acids.
 4. A cell support according to claim 1 inwhich the RGD-enriched gelatine comprises at least 4 RGD motifs,preferably 6, more preferably 8, even more preferably 12 up to andincluding 16 RGD motifs.
 5. A cell support according to claim 1 in whichthe RGD-enriched gelatine has a molecular weight of about 30 kDa toabout 200 kDa.
 6. A cell support according to claim 1 in which theRGD-enriched gelatine has a molecular weight of more than 60 kDa,preferably more than 70 kDa.
 7. A cell support according to claim 1 inwhich the RGD-enriched gelatine has a molecular weight of less thanabout 150 kDa.
 8. A cell support according to claim in which theRGD-enriched gelatine comprises less than 5% hydroxyproline residues,preferably less than 3%.
 9. A cell support according to claim 1 in whichthe RGD-enriched gelatine has a net positive charge at pH 7-7.5.
 10. Acell support according to claim 1 in which the RGD-enriched gelatineconsists for at least 80% of one or more parts of native human collagensequences and said parts of native human collagen sequences have alength of at least 30 amino acids.
 11. A cell support according to claim10 in which the RGD-enriched gelatine consists of one or more parts ofone or more native human collagen sequences.
 12. An RGD-enrichedgelatine in which the percentage of RGD motifs related to the totalnumber of amino acids is at least 0.4 and if the RGD-enriched gelatinecomprises 350 amino acids or more, each stretch of 350 amino acidscontains at least one RGD motif, said gelatine consists for at least 80%of one or more parts of native human collagen sequences and said partsof native human collagen sequences having a length of at least 30 aminoacids.
 13. An RGD-enriched gelatine according claim 12 wherein theRGD-enriched gelatine has a molecular weight of at most 10 kDa,preferably at most 5 kDa.
 14. A cell support comprising an RGD-enrichedgelatine according to claim 12, said cell support being a microcarrier.15. A cell support comprising an RGD-enriched gelatine according toclaim 12, said cell support being selected from the group consisting ofan RGD-enriched coated implant or transplant material, an RGD-enrichedcoated scaffold for tissue engineering, (part of) a dental product,(part of) a wound healing product, (part of artificial skin matrixmaterial and (part of) a tissue adhesive.
 16. Use of an RGD-enrichedgelatine according to claim 12 as a component of drug delivery systems.17. Use of an RGD-enriched gelatine according to claim 13 for inhibitionof cancer metastasis.
 18. Use of an RGD-enriched gelatine according toclaim 12 for prevention of platelet aggregation.
 19. Use of anRGD-enriched gelatine according to claim 13 after surgery to preventtissue adhesion.